

## **ACHIEVE WORLD-CLASS INVESTMENT PERFORMANCE**

April 19, 2024





Research Firm: Market's Risk Is
Phenomenally High, 2nd Dive
Likely


Lawrence Carrel Contributor ©

I'm a journalist who covers finance and investing.

### May 27<sup>th</sup>, 2020:

Ray was interviewed by Forbes to learn about ERS's technology. The full article can be seen online here. Ray was asked "what company does your technology identify as 'very strongest' and what big company was overpriced and risky". ERS's rating for Borg Warner was exceptionally strong and ERS's rating for Bristol Myers was very risky. This chart shows their 12-month performance from the date of the interview.


### Compare the Price Performance of BMY with BWA - 5/27/2020 to 5/27/2021




## THE Forbes Editor Asked For Names of a Strong and a Weak Company. THE FOLLOWING DATA PROVIDES A FAR DEEPER EVALUATION OF ERS'S TECHNOLOGY

On 5/27/20 (see previous slide), a Forbes editor requested that Ray Mullaney, ERS's CEO, select one strong and one weak company from our system. To analyze the effectiveness of the technology, however, he **could** have asked for a list of all the best-rated companies and the worst-rated companies. ERS's technology is rooted in actuarial science, not individual stock selection. The charts below demonstrate the technology's application to 2,247 US companies with market caps over \$500 million.

## Average 3.5-Year Return 5/27/2020 to 11/27/2023



## **Average Return Starting From 5/27/20**





## INVESTLABS\*\*\*

#### A WORLD-CLASS INVESTMENT TECHNOLOGY PLATFORM

ERS's institutional investment research platform, INVESTLABS™, is our crown jewel. After careful study of the competition, we have concluded that INVESTLABS™ is significantly more advanced and valuable to investors than any investment technology platform on the market today.

ERS's database includes over 15,000 U.S. and Canadian companies, both active and delisted, with historical records dating back to 1985. This extensive collection minimizes "survivorship bias", ensuring more accurate analyses.

Among the many tools in INVESTLABS™, our ALPHA SEARCH™ and our DATAMETRICS STRATEGY TESTER™ have undergone independent validations that confirm their accuracy and effectiveness.

ERS's ratings provide a clear picture of a stock's fundamental risks, as well as both the probability and magnitude of future price movements. This platform delivers individual stock ratings, empowers users to evaluate and refine their investment strategies, and devise and test new strategies. This capability is instrumental in assembling portfolios that consistently outperform the market.

We believe ERS's technology is the most valuable investment technology on the market. No other technology comes close.

This screenshot illustrates a portion of the risk evaluation technologies ERS has built.

### InvestLabs™

powered by Equity Risk Sciences

Finding Stocks  Present Stock  Screener  tool to select current stocks which meet your selected financial oriteria, including ERS's proprietary ratings.	Researching Stocks		Monitoring Portfolios	Sites Powered by InvestLabs™
	The Right Criteria™ This tool identifies which of 8 commonly-used financial metrics and 4 proprietary metrics produced the greatest profitability	The Right Price™ This tool quantifies the probability of your selected stock producing a profit within a select date range when purchasing the company at	Risk Table Report This tool allows you to view ERS's ratings on a list of up to 100 stocks and compare their future profitability on any specific date	Exceptional Investing.com FiduciaryRisk
	for a specific stock over a selected time period.	selected metric values.	sand for multiple date ranges.	Ratings.com  GrowMyRIA.com
Historic Portfolio	Price and Risk Chart	Change in Share-	Price Protractor™	KeepMoneySafe.com
Screener A tool to select stocks on a specific past date which meet your selected financial criteria, including ERS's proprietary atings.	5-Color Stock Chart View interactive charts of a selected stock's price and ERS's risk ratings over a specified date range.	holder "Value" Chart View interactive charts of a selected stock's tangible equity and paid in capital over a date range.	Compare the historic probabilities of two stocks producing a gain or loss within a specified time period.	IncomeDuring Retirement.com
				Institutional Capital.ai
Two-Portfolio	Alpha Search™ (One-	Alpha Search (Two-	Superior Sector	InvestingFor
Comparison This tool allows you to select a	Portfolio) Search for all companies that meet	Portfolio) Search for all companies that meet	Screen™ Calculate the performance of all	CPAs.com
inis tool allows you to select a date and two sets of criteria to determine which set of criteria berformed better.	search for air companies that meet selected parameters and calculate their average X-year, Y-month performance from the first day they meet those criteria.	two sets all companies that need two sets of selected parameters and calculate and compare their average X-month performances from the first day they meet those criteria.	stocks which match your specified parameters within each sector on a certain date.	InvestingFor Lawyers.com
				PrepareToRetire.com
Marilet Daniel Ita	Name of the Control o	Charle Durania alla TM	Lancas de Fandes	StockPrognosis.com
Multi Portfolio Screener A tool to select stocks in a range of lates which meet your selected inancial criteria, including ERS's oroprietary ratings, and calculate heir performance.	Multi High/Low Search Insert a group of stock symbols to search for the dates on which they reached their highest or lowest price or rating levels.	Stock Prognosis <sup>TM</sup> Search for all companies with financial metrics similar to those of a specified company on a specified date.	Income-to-Equity Congruency Model	StockRisk Reports.com
				TheBestMetrics.com
				ThePerfectTrade.com
Value-Creation Model	Drawdown Screener Select a set of criteria to screen for stocks and their greatest price drawdowns during the specified date range.	What Must Happen™ Mhat Must Happen™ allows you to determine if a company is likely to produce a profit for you based upon its historic financial	and many more	ValueRatings.com
				WhatMustHappen.com
				and dozens more

## ERS's Robo Technology Enduring Portfolio™ Produces World-Class Results

ERS's technology provides extraordinary results. Over 70% of Americans prefer passive investing to active investing.

ERS has an excellent solution:


ERS's ENDURING PORTFOLIO™!

Statista estimates that robo-advisors manage \$1.37 trillion and growing rapidly.

To serve this growing market, ERS developed the ENDURING PORTFOLIO™.

ERS's fully-automated investing technology has produced world-class results, towering over every robo-advisor in the marketplace.

In 2024, we will turn a spotlight on the ENDURING PORTFOLIO™ and seek joint venture partners to monetize this extraordinary technology.






## ERS'S ROBO TECHNOLOGY FOR GREATER CAPITAL PRESERVATION

ERS has various strategies for different markets. ERS's **CP Robo Technology™** reduced losses during the 2000, 2007 and 2021 market declines by an average of 32% compared to the S&P 500's losses.

ERS's **CP Robo Technology™** generated total wealth of **4.5 times** that of owning an S&P 500 index fund.






## ALPHA ALGORITHMICS™

ERS's ALPHA ALGORITHMICS™ has the potential to compete with James Simons' **Medallion Fund**.


#### Average 6-Month Return – 25-Year Study

12/31/98 to 12/31/23




#### Average 1-Year Return – 25-Year Study

12/31/98 to 12/31/23



# FROM 12/31/2021 TO 12/31/2022 THE S&P 500 FELL 18.1%. ERS'S FIDUCIARY RISK RATING™ PREDICTS THE STATISTICAL PROBABILITY & MAGNITUDE OF STOCK LOSSES

This study quantifies the accuracy and value of ERS's Fiduciary Risk Rating™ (FRR™) on all 5,363 US and Canadian stocks with a market cap over \$100 million in these two periods.



Average 1-Year and 2-Year Return – 12/31/21 to 12/31/22 and to 12/31/23

**Conclusion:** In this period, ERS's **FRR™** rating provided an unequivocal and highly reliable **warning** of the probability of very significant investment losses.



# WHY INVEST IN EQUITY RISK SCIENCES, INC.

"ERS's technology has the potential to produce investment returns on par with the **Medallion Fund**, the most successful fund in US investment history. If successful, we will become a multi-billion-dollar company."

--Raymond Mullaney, CEO

#### **Markets We Serve**

Financial Institutions
RIA Firms
Retail Investors
Bank Trust Companies
Insurance Companies
Family Offices
Hedge Funds
Mutual Funds

#### **Products & Services**

INVESTLABS™

ERS ROBO TECHNOLOGY™

ALPHA ALGORITHMICS™

Proprietary Investment Ratings

Growth Tools for RIAs

Model Portfolio Testers

SaaS-Enabled Investor Websites

#### 506(c) Funding: \$25 million

Shares are offered at \$10.00 per share with a pre-money valuation of \$84 million.

A CT based family office has invested an initial \$500,000.

Additionally, a TN based RIA created a \$4 million fund managed exclusively with ERS's INVESTLABS™ platform.



## FOR MORE INFORMATION

Equity Risk Sciences' technology helps investment managers beat the market, not just sometimes or by a little, but often and by a lot.

Asset managers and investors need, want and will pay handsomely for technology to help them significantly outperform the market and reduce and avoid losses.

For inquiries, collaborations, or a closer look at our breakthrough technologies:

EQUITY RISK SCIENCES, INC.

Raymond M. Mullaney, CEO

Contact: (203) 254-0000

Direct Email: ray@ERS.ai

Email: info@equityrisksciences.com



## **DISCLOSURES**

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Nothing contained in this presentation should be construed as legal, tax, financial, investment, or other advice.

In addition to historical information, this presentation contains statements relating to the future business performance, future catalysts and future events or developments, strategy, prospects, plans, objectives of management and future operations, and expected market growth of Equity Risk Sciences, Inc. (the "Company,") that may constitute "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The words "believe," "can make," "intend," "could," "currently," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.

Important factors that could cause actual results to differ from those in the forward-looking statements include but are not limited to the successful commercialization of our risk rating system and solutions, development of our sales and marketing capabilities, our ability to retain key management personnel including our Founder Ray Mullaney as well as Thomas Harpin, acceptance of our solutions by potential customers, the ability of our risk rating systems and solutions to provide valuable information related to a company's stock price, and intellectual property litigation, and our ability to raise capital necessary for ongoing operations. The statements made herein speak only as of the date of this presentation. The Company's actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. The Company undertakes no obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Market data and industry information used herein are based on our management's knowledge of the industry and the good faith estimates of management. We also relied, to the extent available, upon managements review of independent industry surveys, forecasts and publications and other publicly available information prepared by a number of third-party sources. All of the market data and industry information used herein involves a number of assumptions and limitations which we believe to be reasonable, and you are cautioned not to give undue weight to such estimates. Although we believe that these sources are reliable, we cannot guarantee the accuracy or completeness of this information, and we have not independently verified this information. Projections, assumptions and estimates of our future performance and the future performance of the industry in which we operate are subject to a high degree of uncertainty and risk due to a variety of factors, including those described, above. These and other factors could cause results to differ materially from those expressed in our estimates and beliefs and in the estimates prepared by independent parties. In all cases, you should conduct your own investigation and analysis of the Company and the information contained in this presentation. All estimates and forecasts are subject to change and past results are not necessarily an indication of future performance.

